US 12257239 B1Patent grantUnited States

Multi-Line Cancer Cell Screening Compound

Official patent title

Cytotoxic treatment of cancer cells

Arabic title: معالجة سامة للخلايا السرطانية

Invention

Problem

Cancer remains a major health burden, and existing surgery, radiation, and chemotherapy approaches do not eliminate the need for additional compounds and combination strategies.

Why it matters

Compounds that reduce cancer-cell growth in controlled laboratory studies can provide starting points for drug discovery, although they require extensive safety and efficacy validation.

Approach

The disclosure prepares a substituted thiazolidine-2,4-dione compound and contacts cancer cells with a composition containing it, including combination embodiments with other antineoplastic or chemotherapeutic agents. It reports growth inhibition and IC50 values across several human cancer-cell lines in vitro.

Who may benefit

Potential beneficiaries include oncology drug-discovery groups, medicinal-chemistry laboratories, pharmaceutical research teams, and researchers studying apoptosis-related anticancer mechanisms.

Potential value

The patent links a defined compound-synthesis route with multi-cell-line laboratory activity, apoptosis-related pathway hypotheses, and combination-treatment claim scope in one preclinical package.

Background

Cancer involves uncontrolled growth and spread of abnormal cells and remains a major global health problem. Established treatment options include surgery, radiation, chemotherapy, and combinations of targeted or traditional agents. The publication highlights apoptosis as a research target involving p53, BAX, caspases, BCL-2, MMP2, and MMP9 pathways. It proposes a thiazolidinedione-based compound as another cytotoxic research candidate, but the supplied evidence concerns cell-line experiments rather than animal or human treatment outcomes.

Technology overview

The compound is made by dissolving substituted thiazolidine-2,4-dione and 2-hydroxy-5-nitrobenzaldehyde in a polar protic solvent, adding an acid and heterocyclic amine, and refluxing for six to ten hours. The publication states an 83–87% yield and reports growth-inhibition and IC50 ranges for lung, colorectal, prostate, pharyngeal, breast, and cervical cancer-cell lines. The claims also cover combination with other antineoplastic agents and carrier-based administration forms.

Potential applications

Preclinical screening of a thiazolidinedione compound across cancer-cell lines.
Medicinal-chemistry research on structure, synthesis, and cytotoxic activity.
Laboratory studies of apoptosis-related pathways in treated cancer cells.
Early formulation and combination-therapy research with established agents.

Evidence-supported advantages

The synthesis route specifies reactants, reflux time, and a reported product yield.
Laboratory activity is reported across several distinct human cancer-cell lines.
The disclosure provides both growth-inhibition percentages and selected IC50 ranges.
The claims include combination with other antineoplastic or chemotherapeutic agents.

Development stage

Preclinical in-vitro cell-line testing is described; animal studies, clinical safety, and clinical efficacy were not established.

Commercial opportunity

The compound may be considered for research licensing or joint lead-optimization work. Progress toward a therapeutic would require reproducible selectivity studies, mechanism confirmation, pharmacokinetics, metabolism, formulation, animal efficacy and toxicology, manufacturing controls, and phased clinical and regulatory evaluation. Early comparative benchmarking would also be needed.

Patent classifications

WIPO IPC

A61K31/427Preparations for medical, dental or toiletry purposes

CPC

A61K31/427Preparations for medical, dental or toiletry purposes

Inventors

First inventorTarek Ahmed Yousef
InventorSaad Shaaban
InventorAhmed A. Al-Karmalawy
InventorMarwa Sharaky

Keywords

thiazolidinedione
cancer cells
cytotoxicity
apoptosis
IC50
combination therapy
medicinal chemistry
preclinical oncology

Patent document and drawings

The patent publication is mapped to this record. Patent drawings remain within that publication; no separately cleared public media package has been supplied.